APC/Cyanine7 anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CTL clone V4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
2. Strickley JD, et al. 2019. Nature. 575:519. PubMed
3. Vasanthakumar A, et al. 2020. Nature. 579:581. PubMed
4. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
5. Boyd DF, et al. 2020. Nature. 587:466. PubMed
6. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
7. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
8. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
9. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
10. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
11. Dong L, et al. 2021. Cancer Cell. . PubMed
12. Shao B, et al. 2018. Mol Med Rep. 18:920. PubMed
13. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
14. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
15. Pandey S, et al. 2020. Cell Syst. 11:495. PubMed
16. Chen J, et al. 2021. Sci Adv. 7:. PubMed
17. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
18. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
19. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
20. Saito S, et al. 2020. Nutrients. 12:. PubMed
21. Lutes LK, et al. 2021. eLife. 10:00. PubMed
22. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
23. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
24. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
25. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
26. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
27. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
28. Ciarlo E, et al. 2016. Sci Rep. 6:37944. PubMed
29. Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
30. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
31. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
32. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
33. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
34. Yu X, et al. 2022. J Extracell Vesicles. 11:e12185. PubMed
35. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
36. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
37. Levi J, et al. 2020. J Nucl Med. . PubMed
38. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
39. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
40. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
41. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
42. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
43. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
44. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
45. Ma W, et al. 2017. Sci Rep. . 10.1038/s41598-017-15661-6. PubMed
46. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
47. Shi R, et al. 2022. Theranostics. 12:875. PubMed
48. Gary E, et al. 2020. Vaccine. 3821:38. PubMed
49. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
50. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
51. Wennerberg E, et al. 2022. Sci Transl Med. 14:eabe8195. PubMed
52. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
53. Mara AB, et al. 2022. NPJ Vaccines. 7:86. PubMed
54. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
55. Zhang L, et al. 2021. Clin Transl Med. 11:e464. PubMed
56. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
57. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
58. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
59. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
60. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
61. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
62. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
63. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
64. Brown SM et al. 2017. Endocrinology. 158(10):3592-3604 . PubMed
65. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
66. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
67. Yang S, et al. 2022. J Exp Med. 219:. PubMed
68. Ding P, et al. 2022. Bone Res. 10:42. PubMed
69. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
70. Sadik A, et al. 2020. Cell. 1252:182. PubMed
71. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
72. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
73. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
74. Yeung F, et al. 2020. Cell Host & Microbe. 27(5):809-822. PubMed
75. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
76. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
77. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
78. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
79. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
80. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
81. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
82. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
83. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
84. McNamee E, et al. 2013. Gut. 62:53. PubMed
85. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
86. Wang X, et al. 2021. Cell. 184:5357. PubMed
87. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
88. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
89. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
90. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
91. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
92. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
93. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
94. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
95. Ma C, et al. 2021. J Exp Med. :218. PubMed
96. Wang M, et al. 2021. iScience. 24(7):102766. PubMed
97. Sheng J, et al. 2021. eLife. 10:00. PubMed
98. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
99. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
100. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
101. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
102. Chen B, et al. 2021. Cell. 184:6262. PubMed
103. Wang X, et al. 2022. Elife. 11:. PubMed
104. Sen D, et al. 2016. PLoS One. 11:e0165064. PubMed
105. Young JS, et al. 2018. Front Immunol. 9:1385. PubMed
106. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
107. Liu A, et al. 2022. Front Cell Infect Microbiol. 12:960208. PubMed
108. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
109. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
110. Ma C, et al. 2020. Sci Adv. 6:eaaz6717. PubMed
111. Wolf Y, et al. 2019. Cell. 179:219. PubMed
112. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed
113. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
114. Liang Z, et al. 2022. iScience. 25:105233. PubMed
115. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
116. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed

RRID

AB_312698 (BioLegend Cat. No. 100413)
AB_312699 (BioLegend Cat. No. 100414)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis